to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Cell Line, Tumor
Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival.
Glucocorticoid receptor activation signals through forkhead transcription factor 3a in breast cancer cells.
Ubiquitin-proteasome degradation of serum- and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperone-dependent E3 ligase CHIP.
Hsp90 regulates the phosphorylation and activity of serum- and glucocorticoid-regulated kinase-1.
Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
The MAP kinase phosphatase-1 MKP-1/DUSP1 is a regulator of human liver response to transplantation.
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.
Serum- and glucocorticoid-induced protein kinase 1 (SGK1) is regulated by store-operated Ca2+ entry and mediates cytoprotection against necrotic cell death.
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth.
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
Survival Signaling in Breast Cancer
Tumor Cell Lines